BIVI
MaterialsBioVie Inc - Class A
Live · NASDAQ · May 9, Close
What's Moving BIVI Today?
No stock-specific AI insight has been generated for BIVI yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
BIVI News
20 articles- BioVie advances long COVID trial, top-line data expected by summerYahoo Finance·May 4, 2026
- BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026Yahoo Finance·Apr 27, 2026
- RedChip's Biotech Investor Conference Replays Now AvailableYahoo Finance·Apr 20, 2026
- BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual MeetingYahoo Finance·Apr 14, 2026
- BioVie abstract on Parkinson’s drug accepted for neurology conferenceProactive Investors·Apr 14, 2026
- BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMIProactive Investors·Apr 11, 2026
- BioVie targets neuroinflammation and insulin resistance in Parkinson’s treatment approachYahoo Finance·Apr 9, 2026
- RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor ConferenceYahoo Finance·Apr 2, 2026
- BioVie to present Parkinson’s study data at AD/PD 2026 conferenceProactive Investors·Mar 12, 2026
- BioVie Announces Abstract Accepted for Presentation at AD/PD 2026Yahoo Finance·Mar 12, 2026
- 60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Feb 27, 2026
- Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4Yahoo Finance·Feb 23, 2026
- New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin AmericaYahoo Finance·Feb 21, 2026
- BioVie highlights bezisterim research at ACP meetingProactive Investors·Feb 12, 2026
- BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual MeetingYahoo Finance·Feb 12, 2026
- BioVie could offer first new Parkinson’s therapy in decadesProactive Investors·Feb 11, 2026
- New to The Street Broadcasts Show #716 Tonight at 6:30 PM ET on Bloomberg Television Featuring Stardust Power (NASDAQ:SDST), BioVie (NASDAQ:BIVI), Roadzen (NASDAQ:RDZN), with Special Segments from Kelsey Grammer on KAREN and Andrew Shaw of 250DAYS.ORGYahoo Finance·Jan 17, 2026
- BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s DiseaseYahoo Finance·Jan 8, 2026
- Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme TherapeuticsYahoo Finance·Dec 17, 2025
- What Makes BioVie (BIVI) a New Buy StockYahoo Finance·Dec 11, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About BioVie Inc - Class A
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.